Does Anticomplement Therapy Have a Role in the Management of Malignant Hypertension?

Journal of Clinical Hypertension

Volumn 18, Issue 4, 2016, Pages 359-360

  Tsai, Han Mou ^a  

^a IMAH Hematology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ECULIZUMAB; ANTICOMPLEMENT; COMPLEMENT INHIBITOR;

ABDOMINAL PAIN; ADULT; ANOREXIA; BLOOD PRESSURE MEASUREMENT; CASE REPORT; COUGHING; CREATININE BLOOD LEVEL; DISEASE DURATION; DYSPNEA; HEADACHE; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HOSPITAL ADMISSION; HUMAN; KIDNEY FAILURE; LETTER; MALE; MALIGNANT HYPERTENSION; MIDDLE AGED; NAUSEA; PATIENT REFERRAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; UREMIA; VOMITING; BLOOD PRESSURE; DRUG EFFECTS; HYPERTENSION, MALIGNANT; PATHOPHYSIOLOGY;

BLOOD PRESSURE; COMPLEMENT INACTIVATOR PROTEINS; HUMANS; HYPERTENSION, MALIGNANT; MALE; MIDDLE AGED;

EID: 84941578539     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12664     Document Type: Letter

References (10)

1. Isles CG, McLay A, Jones JM. Recovery in malignant hypertension presenting as acute renal failure. Q J Med. 1984;53:439-452.
2. van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension. 2005;45:246-251.
3. Amraoui F, Bos S, Vogt L, van den Born BJ. Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study. BMC Nephrol. 2012;13:71.
4. Amraoui F, van der Hoeven NV, Van Valkengoed IG, et al. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. J Clin Hypertens (Greenwich). 2014;16:122-126.
5. Sinclair RA, Antonovych TT, Mostofi FK. Renal proliferative arteriopathies and associated glomerular changes: a light and electron microscopic study. Hum Pathol. 1976;7:565-588.
6. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169-2181.
7. Tsai HM. A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome. Transfus Med Rev. 2014;28:187-197.
8. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859.
9. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554-562.
10. Tsai HM, Kuo E. Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome. Adv Hematol. 2014;2014:295323.